We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

TAILORx Tissue Bank

This study is currently recruiting participants.
Verified August 2017 by Cancer Trials Ireland
Sponsor:
ClinicalTrials.gov Identifier:
NCT02050750
First Posted: January 31, 2014
Last Update Posted: August 10, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Cancer Trials Ireland
January 24, 2014
January 31, 2014
August 10, 2017
December 2013
June 2018   (Final data collection date for primary outcome measure)
Disease relapse, endocrine and/or chemotherapy resistance prognosis [ Time Frame: For duration of follow up, expected 10 years ]
A biobank, TMAs and full face sections, will allow for the identification of candidate/novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance
Same as current
Complete list of historical versions of study NCT02050750 on ClinicalTrials.gov Archive Site
Signature/biomarkers [ Time Frame: For the duration of follow up, expected 10 years ]
Validation of emerging signature/biomarkers
Same as current
Not Provided
Not Provided
 
TAILORx Tissue Bank
Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)
This is an exploratory, translational, non-interventional and multi-centre biobank. The aim of the development of such a biobank is to identify potential biomarkers that are indicative of disease relapse.

The primary objective is to develop a biobank, tissue microarrays (TMAs) and full face sections, which will be used to identify candidate/ novel biomarkers prognostic for disease relapse and predictive for endocrine and/or chemotherapy resistance.

The secondary objectives are:

  • To validate emerging signatures/biomarkers identified.
  • To develop new assays for the breast cancer clinic.
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
The study population will consist only of patients that participated in the TAILORx ICORG 06-31 trial. These patients must have participated in trial arms relevant to ICORG 06-31 study and have adequate tumour tissue available.
Breast Cancer
Not Provided
TAILORx ICORG 06-31
Patients must have participated in TAILORx ICORG 06-31, participated in trial arms, and have adequate tumour tissue available
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
690
Not Provided
June 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients that were registered with the ICORG 06-31 TAILORx trial and participated in trial arms
  • Patients with adequate tumor tissue available
Sexes Eligible for Study: Female
18 Years to 75 Years   (Adult, Senior)
No
Ireland
 
 
NCT02050750
ICORG 12-30
No
Not Provided
Not Provided
Cancer Trials Ireland
Cancer Trials Ireland
Not Provided
Not Provided
Cancer Trials Ireland
August 2017